50 results
424B3
CYTH
Cyclo Therapeutics Inc - Ordinary Shares
21 Nov 23
Prospectus supplement
9:15am
clinical studies suggest that Trappsol® Cyclo™ clears toxic deposits of cholesterol and other lipids from cells, has a consistent pharmacokinetic profile … .
Preliminary data from Cyclo’s completed clinical studies suggest that Trappsol® Cyclo™ clears toxic deposits of cholesterol and other lipids from cells, has
S-4/A
CYTH
Cyclo Therapeutics Inc - Ordinary Shares
20 Nov 23
Registration of securities issued in business combination transactions (amended)
8:50am
that Trappsol® Cyclo™ clears toxic deposits of cholesterol and other lipids from cells, has a consistent pharmacokinetic profile peripherally, and crosses … completed clinical studies suggest that Trappsol® Cyclo™ clears toxic deposits of cholesterol and other lipids from cells, has a consistent pharmacokinetic
S-4
CYTH
Cyclo Therapeutics Inc - Ordinary Shares
7 Nov 23
Registration of securities issued in business combination transactions
4:45pm
clinical studies suggest that Trappsol® Cyclo™ clears toxic deposits of cholesterol and other lipids from cells, has a consistent pharmacokinetic profile
8-K
EX-10.1
iiy0fdf402v dan
20 Oct 23
Unregistered Sales of Equity Securities
2:19pm
8-K
EX-10.1
l4hgnba44rz 1l
5 Jun 23
Entry into a Material Definitive Agreement
9:22am
8-K
EX-10.1
slwxd
4 May 23
Unregistered Sales of Equity Securities
3:42pm
8-K
EX-10.1
9s7vk
24 Apr 23
Unregistered Sales of Equity Securities
9:24am
8-K
EX-1.1
y01536cmrh ofryt
19 Nov 21
Cyclo Therapeutics Announces Pricing of $11.7 Million Underwritten Public Offering of Common stock
4:04pm
8-K
EX-10.1
nhrnx
16 Aug 21
Entry into a Material Definitive Agreement
4:52pm
8-K
EX-1.1
ctcb zkumv6h5a
11 Dec 20
Cyclo Therapeutics Announces Pricing of $12.5 Million Public Offering
4:02pm
424B4
q3kt3fv
11 Dec 20
Prospectus supplement with pricing info
1:38pm
424B4
cxsr ne0amjee5wk
11 Dec 20
Prospectus supplement with pricing info
12:00am